Industrialized Drug Discovery with the Evosep One

Drug discovery has advanced into a highly complex and regulated process, requiring the seamless integration of biology, chemistry, and pharmacology. Over the past decades, the increasing demand for preclinical validation, clinical trials, and regulatory approvals has emphasized the need for more efficient analytical workflows.

To accelerate innovation while maintaining data quality, high-throughput and robust analytical methods are essential. In this webinar, we explore how Evosep One is shaping industrialized drug discovery by enabling higher sensitivity, reproducibility, and scalability—critical factors in developing new drug applications and biologics license applications.

Join us to learn how industrialized proteomics can enhance drug discovery pipelines, reduce bottlenecks, and bring safer treatments to patients faster.

Proteomics Empowering Drug Discovery & Translational Research – “Are We There Yet?”

Presenter: Ashok Dongre (Senior Director & Head of Proteomics at Bristol-Myers Squibb)

Proteomics has evolved over the past 25+ years, experiencing a recent renaissance with the adoption of various transformative methodologies, including mass spectrometry and reagent-based profiling approaches. While proteomics has made significant progress, it still faces barriers to widespread adoption in biological and biopharma research. This presentation aims to showcase how advancements in next-gen LC-MS technology and deep learning data analytics can provide actionable insights for drug discovery and translational research. By addressing complex questions at the intersection of disease pathophysiology and biopharma research, proteomics can have a profound impact. This marks the beginning of what is possible with proteomics, as Winston Churchill said, “…it is perhaps the end of the beginning.”

Decoding PPIs: Insights from APMS and Convergent Network Biology

Presenter: Chris Adams, Director of Proteomics at Rezo Therapeutics

Understanding drug action at the molecular level requires a comprehensive view of protein-protein interaction (PPI) networks. In this talk, I will present our approach to elucidating novel drug targets using network analysis and affinity purification mass spectrometry (AP-MS). By investigating differential PPI networks in response to drug treatment, we identify key regulatory hubs and pathway alterations. This integrative strategy enhances our ability to uncover mechanistic insights and guide rational drug development.